Dermatology

Etanercept found equally effective treating plaque psoriasis compared with Enbrel.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

The FDA has approved the supplemental biologics license application for the expanded use of Enbrel (etanercept).

Elevated rates of fibromyalgia found in patients with rheumatic diseases, such as psoriatic arthritis.

Enbrel is now indicated in pediatric patients with moderate-to-severe plaque psoriasis.

Ustekinumab is a monoclonal antibody approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNF therapy in psoriatic arthritis.

Few prior studies have evaluated the relative effectiveness of earlier and later lines of TNFi therapy in psoriatic arthritis.

Atopic Dermatitis (AD) is a chronic, pruritic, relapsing inflammatory skin disease. AD onset is most common between 3 months and 6 months of age, with approximately 60% of patients developing the eruption in the first year of life and 90% by 5 years of age. The majority of affected individuals (70% to 90%) have resolution of disease by adulthood

This Continuing Education activity is supported by an educational grant from Lilly.

This retrospective study compared the treatment patterns of ustekinumab with recommended maintenance administration every 12 weeks, with adalimumab and etanercept, administered weekly or every other week, for the treatment of plaque psoriasis.

Dupilumab shows benefits for the treatment of asthma and atopic dermatitis.

A survey from Novartis revealed that 57% of patients with psoriasis did not achieve clear or almost clear skin.

Early intervention beneficial for pediatric eczema or atopic dermatitis in infants.

Study findings contribute to the development of personalized treatment approaches for young children with eczema.

Crisaborole topical ointment shows promise in treating atopic dermatitis.

Top news of the day from across the health care landscape.

Dupilumab is an investigational antibody treatment for inadequately controlled moderate-to-severe atopic dermatitis.

Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.

Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.

Trial shows no increased incidence of adverse events or any new safety signals with exposure to Otezla.

Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.

Amgen’s biosimilar Amjevita approved for variety of anti-inflammatory diseases, however, ongoing litigation may prevent it from hitting the market.

Refunds will be offered to plan sponsors if a patient discontinues a preferred anti-inflammatory drug within 90 days.

Allergan plans to acquire Vitae Pharmaceuticals and their experimental dermatology drugs.

New research compares cardiovascular issues among patients with type 2 diabetes and psoriasis.